首页> 外文OA文献 >Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

【2h】

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

机译：静脉静脉曲张与12个月的辅助曲妥珠单抗与Her2阳性乳腺癌的妇女组合组合：Hellenic肿瘤学研究组（Horg）的多中心随机研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D. Mavroudis; E. Saloustros; N. Malamos; S. Kakolyris; I. Boukovinas; P. Papakotoulas; N. Kentepozidis; N. Ziras; V. Georgoulias;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) (vol 26, pg 1333, 2015) [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第3期

机译：六个月的佐剂曲妥珠单抗与Her2阳性乳腺癌的妇女组合组合：Hellenic肿瘤学研究组（Horg）的多中心随机研究（Vol 26，PG 1333,2015）
2. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) [J] . Mavroudis D., Saloustros E., Malamos N., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第7期

机译：6到12个月辅助曲妥珠单抗联合剂量密集化疗治疗HER2阳性乳腺癌妇女：希腊肿瘤研究小组（HORG）进行的多中心随机研究
3. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) [J] . Mavroudis D., Saloustros E., Malamos N., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第7期

机译：六个月与12个月的佐剂曲妥珠单抗与Her2阳性乳腺癌的妇女组合组合：Hellenic肿瘤研究组（Horg）的多中心随机研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Dose-dense sequential adjuvant chemotherapy followed as indicated by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial [O] . George Fountzilas, Urania Dafni, Christos Papadimitriou, 2014

机译：如所示在早期乳腺癌患者中进行了剂量密集的序贯辅助化疗随后是曲妥珠单抗治疗了一年：希腊合作肿瘤小组随机III期临床试验的5年中位随访首次报道
7. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG) [O] . Polyzos, Aristides, Malamos, Nikolaos, Boukovinas, Ioannis, 2009

机译：FEC与序贯多西紫杉醇联合表柔比星/环磷酰胺作为腋窝淋巴结阳性早期乳腺癌妇女的辅助化疗：古希腊肿瘤研究组（HORG）的一项随机研究

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

著录项

引文网络

相似文献

相关主题

期刊订阅